December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP:RLFTF)

2.120 +0.179 (+9.19%)
Streaming Delayed Price Updated: 3:03 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relief Therapeutics Hldg Ag

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
News headline image
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Via ACCESSWIRE
News headline image
Relief Therapeutics to Participate in January Investor Meetings
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Executive Leadership Team Changes
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
Via ACCESSWIRE
News headline image
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
Via ACCESSWIRE
News headline image
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
News headline image
Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate ↗
 
Via Benzinga
News headline image
Relief Announces U.S. Launch of PKU GOLIKE
Via ACCESSWIRE
News headline image
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
Via ACCESSWIRE
News headline image
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Via ACCESSWIRE
News headline image
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Via ACCESSWIRE
News headline image
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement
Via ACCESSWIRE
News headline image
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
Via ACCESSWIRE
News headline image
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
Via ACCESSWIRE
News headline image
Relief Reports Half-Year 2022 Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Via ACCESSWIRE
News headline image
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
News headline image
Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
News headline image
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
Via ACCESSWIRE
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
GENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ")... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
News headline image
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), today announced that its collaboration partner, ACER Therapeutics, Inc.... 
From Relief Therapeutics Holdings AG
Via AccessWire
News headline image
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Experienced Leader in Commercial and Medical Affairs, With a Focus on Gene Therapy, to Spearhead Relief's New Strategic Foray Into Genetic Medicine 
From Relief Therapeutics Holdings AG
Via AccessWire
News headline image
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Company acquires an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United Kingdom, thereby complementing and enhancing its... 
From Relief Therapeutics Holdings AG
Via AccessWire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.